Last $83.74 USD
Change Today +1.53 / 1.86%
Volume 1.2M
MJN On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

mead johnson nutrition co (MJN) Snapshot

Open
$83.12
Previous Close
$82.21
Day High
$83.90
Day Low
$83.12
52 Week High
04/4/14 - $87.00
52 Week Low
07/3/13 - $66.80
Market Cap
16.9B
Average Volume 10 Days
1.6M
EPS TTM
$3.40
Shares Outstanding
202.1M
EX-Date
03/13/14
P/E TM
24.7x
Dividend
$1.50
Dividend Yield
1.67%
Current Stock Chart for MEAD JOHNSON NUTRITION CO (MJN)

mead johnson nutrition co (MJN) Related Businessweek News

View More BusinessWeek News

mead johnson nutrition co (MJN) Details

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. Its infant formula products include formulas for routine feeding; solutions formulas for addressing mild feeding problems, such as gas/fussiness, soy formula, lactose intolerance, anti-regurgitation, and cow’s milk protein allergy risk; and specialty formula products, including formulas for addressing severe intolerance, formulas for premature and low birth weight infants, and medical nutrition products. Its children’s nutrition products comprise products for meeting children’s nutritional needs at one to three years of age, three to five years of age, and beyond five years of age. The company’s children’s nutrition products also include nutritionally-balanced milk supplements for children targeting nutritional needs during specific stages of development; powered milk supplements; and milk modifiers in powder form. It also produces a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers. The company markets its products primarily under the Enfamil Premium, Enfamil Premium Newborn, Enfamil A+, Enfalac A+, Enfapro A+, Enfamil Gentlease, Enfapro Premium, SanCor Bebé, SanCor Bebé Premium, Enfamil ProSobee, Enfamil LactoFree, Enfamil AR, Enfamil HA, Enfamil Comfort, Enfamil for Supplementing, Nutramigen, Nutramigen AA, Pregestimil, Enfamil Premature, Enfacare, Enfagrow, Enfagrow A+, Enfagrow Premium, Enfamil Human Milk Fortifier, Sustagen KID, Lactum, Alacta, ChocoMilk, and Cal-C-Tose brand names. It sells its products to mothers, health care professionals, and retailers in approximately 50 countries in North America, Europe, Asia, and Latin America. The company was founded in 1905 and is headquartered in Glenview, Illinois.

7,200 Employees
Last Reported Date: 02/18/14
Founded in 1905

mead johnson nutrition co (MJN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $893.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $603.8K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $548.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $454.6K
Senior Vice President of Global Supply Chain
Total Annual Compensation: $377.3K
Compensation as of Fiscal Year 2013.

mead johnson nutrition co (MJN) Key Developments

Mead Johnson Nutrition Company Declares Regular Quarterly Dividend for the Quarter Ending March 31, 2014, Payable on April 1, 2014

Mead Johnson Nutrition Company announced that its board of directors has declared a regular quarterly dividend of $0.375 per share for the quarter ending March 31, 2014, a 10% increase from the prior rate of $0.34 per share. The board expects the annualized dividend to be $1.50 per share. The dividend will be paid at the new higher rate on April 1, 2014, to shareholders of record at close of business on March 17, 2014.

Mead Johnson Nutrition Company Appoints Michael Grobstein as Director

On February 27, 2014, the Board of Directors of Mead Johnson Nutrition Company voted to increase the current size of the Board from 11 to 12 members, as permitted by the company's Amended and Restated Certificate of Incorporation. Upon recommendation of the Nominating and Corporate Governance Committee, on February 27, 2014, the Board appointed Mr. Michael Grobstein, effective immediately, to fill the vacancy created by the increase in the number of directors. He is a retired Vice Chairman of Ernst & Young LLP. Mr. Grobstein is currently on the board of directors of Bristol-Myers Squibb, where he is a member of the audit committee, as well as the compensation and management development committees. He was also a director of Given Imaging Ltd., where he served on several committees and was chair of the audit committee, until its recent acquisition by Covidien plc. Mr. Grobstein currently serves on the boards of the Central Park Conservancy and the Peer Health Exchange.

Mead Johnson Nutrition Company Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for 2014

Mead Johnson Nutrition Company announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported that sales totaled $1,060.7 million, up 8% from $981.1 million in the prior-year quarter. Net earnings attributable to shareholders totaled $153.2 million, or $0.75 per diluted share, in the fourth quarter of 2013, compared to $134.2 million, or $0.66 per diluted share, in the prior-year quarter. On a non-GAAP basis, excluding specified Items, net earnings attributable to shareholders totaled $157.9 million, or $0.78 per diluted share, for the fourth quarter of 2013, compared to $146.7 million, or $0.72 per diluted share, for the same quarter a year ago. Earnings before interest and income taxes were $205.2 million against $189.7 million a year ago. Earnings before income taxes were $193.5 million against $173.7 million a year ago. Non-GAAP EBIT was $213.6 million against $207.8 million a year ago. For the year, the company reported that sales totaled $4,200.7 million up 8% from $3,901.3 million a year ago. Sales increased 5% from volume and 4% from price, reduced by 1% from foreign exchange. EBIT for 2013 totaled $924.6 million, up from $870.0 million in 2012. The EBIT increase was driven by sales growth and improved gross margin, partially offset by record demand-generation spending and higher pension settlement expense. Net earnings attributable to shareholders for 2013 totaled $649.5 million, or $3.19 per diluted share, compared to $604.5 million, or $2.95 per diluted share, for 2012. On a non-GAAP basis, excluding specified Items, net earnings attributable to shareholders totaled $687.6 million, or $3.38 per diluted share in 2013, up 9% from $630.1 million, or $3.08 per diluted share in 2012. Earnings before income taxes were $874.0 million against $805.0 million a year ago. Net cash provided by operating activities was $806.6 million against $692.7 million a year ago. Payments for capital expenditures were $240.4 million against $124.4 million a year ago. Non-GAAP EBIT was $969.8 million against $907.3 million a year ago. The company expects full-year 2014 non-GAAP EPS to be in the range of $3.50 to $3.62. The company estimates Specified Items at $0.06 per diluted share. As a result full-year GAAP EPS is expected to be in the range of $3.44 to $3.56. The company is planning to adopt mark-to-market pension accounting (MTM) during the first quarter of 2014. The non-GAAP and GAAP EPS guidance does not reflect this change in accounting methodology. The periodic MTM adjustment will be reflected as a Specified Item and therefore excluded from the calculation of non-GAAP earnings. As a result, the company expects the change in accounting to have a positive impact on 2014 non-GAAP earnings. This will not, however, reflect a change in the underlying business performance. The company expects global tax rate in 2014 to be in the range of 24% to 24.5%, in line with 2013 results. The company said that higher pricing, coupled with several productivity gains, are expected to help maintain gross margins at or slightly below 62.5% in 2014, well within the range of longer-term average. The company said that gross margins and operating expenses, 2014 EBIT margins are expected to be in the range of 23% to 23.5%. The company expects gross margin about 62.5% or slightly below that for the full year 2014. For 2014, capital spending is estimated at $180 million. Depreciation and amortization expense is expected to be around $90 million, up from $83 million as production from the Singapore plant starts midyear. The company said that if exchange rates remain at their current level throughout 2014, it expects translation impacts to reduce sales by about 2.5% with an unfavorable impact on earnings per share of $0.08 compared to 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MJN:US $83.74 USD +1.53

MJN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Perrigo Co PLC $143.32 USD +2.46
Pfizer Ltd/India 1,239 INR +8.15
Kalbe Farma Tbk PT 1,540 +5.00
Synutra International Inc $5.73 USD +0.08
Hain Celestial Group Inc/The $85.65 USD +0.67
View Industry Companies
 

Industry Analysis

MJN

Industry Average

Valuation MJN Industry Range
Price/Earnings 25.8x
Price/Sales 3.9x
Price/Book 56.9x
Price/Cash Flow 25.6x
TEV/Sales 3.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEAD JOHNSON NUTRITION CO, please visit www.mjn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.